Diabetic Kidney Disease Clinical Trials | A Drug Pipeline Analysis Report 2024 | Bayer, Gilead Sciences, Kyowa Kirin, Dimerix

United States, Nevada, Las Vegas, DelveInsight's 'Diabetic Kidney Disease Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Kidney Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Kidney Disease pipeline domain.
Download our free sample report @ https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Diabetic Kidney Disease Pipeline Report
Leading Diabetic Kidney Disease companies developing novel drug candidates to improve the Diabetic Kidney Disease treatment landscape include Bayer, Gilead Sciences, Kyowa Kirin, Dimerix, and others.
Promising Diabetic Kidney Disease pipeline therapies in various stages of development include Finerenone (BAY94-8862), Selonsertib (SEL), Bardoxolone methyl, DMX-200, and others.
Diabetic Kidney Disease Overview
Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a complication of diabetes mellitus that affects the kidneys. It is characterized by damage to the kidneys' filtering units (glomeruli) due to long-standing diabetes and elevated blood sugar levels. Here's an overview covering its causes, signs and symptoms, diagnosis, and treatment options:

Diabetic Kidney Disease Causes:
The primary cause of diabetic kidney disease is prolonged exposure to high blood sugar levels (hyperglycemia) associated with diabetes mellitus. Other contributing factors include:

1. Glomerular hypertension and hyperfiltration: High blood sugar damages the small blood vessels (capillaries) in the glomeruli, leading to increased pressure and hyperfiltration in the kidneys.

2. Proteinuria: Over time, damage to the glomeruli results in leakage of proteins (especially albumin) into the urine (proteinuria), which further contributes to kidney damage.

3. Activation of inflammatory and fibrotic pathways: Chronic inflammation and fibrosis in the kidneys accelerate the progression of diabetic kidney disease.

4. Genetic predisposition: Some individuals may have genetic factors that make them more susceptible to diabetic kidney disease.

Diabetic Kidney Disease Signs and Symptoms:
In the early stages, diabetic kidney disease may not cause noticeable symptoms. As the condition progresses, signs and symptoms may include:

1. Proteinuria: Excess protein in the urine, detected through urine tests.

2. Edema: Swelling, particularly in the legs, ankles, or around the eyes, due to fluid retention.

3. Hypertension: High blood pressure, often worsening as kidney function declines.

4. Fatigue and weakness: Generalized tiredness and reduced energy levels.

5. Changes in urination: Decreased urine output, increased frequency of urination, especially at night (nocturia), or foamy urine.

Diabetic Kidney Disease Diagnosis:
1. Urine Tests:
- Urinalysis: Detects proteinuria, hematuria (blood in urine), and other abnormalities.
- Albumin-to-creatinine ratio (ACR): Measures the amount of albumin in the urine relative to creatinine, indicating kidney damage.

2. Blood Tests:
- Serum creatinine and estimated glomerular filtration rate (eGFR): Measures kidney function. Creatinine levels increase as kidney function declines, and eGFR estimates how well the kidneys are filtering waste products from the blood.
- Blood glucose and hemoglobin A1C: To assess diabetes control.

3. Imaging Studies:
- Ultrasound: To visualize the kidneys and assess their size and structure.

4. Kidney Biopsy: In some cases, a biopsy may be performed to examine a small sample of kidney tissue under a microscope, particularly if the diagnosis is uncertain or if other kidney diseases are suspected.

Diabetic Kidney Disease Treatment Options:
The goals of treatment for diabetic kidney disease are to slow its progression, manage complications, and preserve kidney function:

1. Blood Sugar Control: Tight control of blood glucose levels through diet, exercise, and medications (insulin or oral hypoglycemic agents) is essential to prevent further kidney damage.

2. Blood Pressure Management: Controlling hypertension (high blood pressure) with medications such as ACE inhibitors or angiotensin II receptor blockers (ARBs) is crucial. These medications also help reduce proteinuria and protect kidney function.

3. Protein Restriction: Limiting dietary protein intake may be recommended to reduce the workload on the kidneys.

4. Cholesterol Management: Statin medications may be prescribed to manage cholesterol levels and reduce cardiovascular risk.

5. Diuretics: These medications may be used to reduce edema and manage fluid retention.

6. Dialysis and Kidney Transplant: In advanced stages of diabetic kidney disease, dialysis (hemodialysis or peritoneal dialysis) or kidney transplantation may be necessary.

7. Lifestyle Modifications: Adopting a healthy lifestyle with a balanced diet, regular exercise, smoking cessation, and avoiding excessive alcohol consumption can help manage diabetes and reduce the risk of complications.

Diabetic Kidney Disease Market Outlook:
The prognosis for diabetic kidney disease varies depending on factors such as the stage of the disease at diagnosis, the effectiveness of treatment, and the presence of other medical conditions. Early detection and management are crucial to slowing progression and preserving kidney function. Regular monitoring by healthcare providers, adherence to treatment recommendations, and lifestyle modifications are essential for optimizing outcomes and reducing the risk of complications associated with diabetic kidney disease.

Request for a sample report @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Diabetic Kidney Disease Pipeline Analysis: Drug Profile
Finerenone (BAY94-8862) by Bayer, which is a nonsteroidal mineralocorticoid receptor antagonist in development for the treatment of diabetic kidney disease. It blocks the detrimental effects due to over activation of the receptor by aldosterone and cortisol, which increases blood pressure and has been implicated in a number of other deleterious effects in the kidney, vasculature, and heart. While aldosterone secretion is inhibited by angiotensin- converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Currently, the drug is in phase III stage of clinical development for DKD.
Discover more about the emerging Diabetic Kidney Disease drugs @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Diabetic Kidney Disease Key Companies
Bayer
Gilead Sciences
Kyowa Kirin
Dimerix
Diabetic Kidney Disease Pipeline Therapies
Finerenone (BAY94-8862)
Selonsertib (SEL)
Bardoxolone methyl
DMX-200
Diabetic Kidney Disease Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Diabetic Kidney Disease Pipeline Report
Coverage: Global
Key Diabetic Kidney Disease Companies: Bayer, Gilead Sciences, Kyowa Kirin, Dimerix, and others
Key Diabetic Kidney Disease Pipeline Therapies: Finerenone (BAY94-8862), Selonsertib (SEL), Bardoxolone methyl, DMX-200, and others
Find out more about the Diabetic Kidney Disease treatment options in development @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
To know more about Diabetic Kidney Disease Pipeline Segment, visit: https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Leber's Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight:

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.